Terns Pharmaceuticals Inc (TERN)
5.79
+0.08
(+1.40%)
USD |
NASDAQ |
Nov 22, 16:00
5.79
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Cash from Financing (Quarterly): 163.29M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 163.29M |
| June 30, 2024 | 0.399M |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 13.86M |
| September 30, 2023 | 0.02M |
| June 30, 2023 | 0.489M |
| March 31, 2023 | 27.58M |
| December 31, 2022 | 105.97M |
| September 30, 2022 | 61.00M |
| June 30, 2022 | 0.124M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.016M |
| September 30, 2021 | 0.797M |
| June 30, 2021 | -1.589M |
| March 31, 2021 | 135.17M |
| December 31, 2020 | 68.64M |
| September 30, 2020 | 0.032M |
| June 30, 2020 | 16.88M |
| March 31, 2020 | -0.033M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.589M
Minimum
Jun 2021
163.29M
Maximum
Sep 2024
31.19M
Average
0.489M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 211.30M |
| Viking Therapeutics Inc | 2.522M |
| Biomarin Pharmaceutical Inc | -499.12M |
| Elite Pharmaceuticals Inc | -0.3207M |
| Verrica Pharmaceuticals Inc | -0.397M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.46M |
| Cash from Investing (Quarterly) | 31.75M |
| Free Cash Flow | -74.83M |
| Free Cash Flow Per Share (Quarterly) | -0.2115 |
| Free Cash Flow Yield | -17.29% |